Skin Related Problems Among Women of Reproductive Age Suffering from Polycystic Ovarian

Anam Hassan; Rashida Akbar; Hira Mustafa; Summiya Ali; Zara; Seema

doi:10.70749/ijbr.v3i4.2637

Authors

Anam Hassan Department of Obstetrics & Gynecology, People's University of Medical and Health Sciences for Women, Shaheed Benazirabad, Sindh, Pakistan
Rashida Akbar Department of Obstetrics & Gynecology, People's University of Medical and Health Sciences for Women, Shaheed Benazirabad, Sindh, Pakistan
Hira Mustafa Department of Obstetrics & Gynecology, People's University of Medical and Health Sciences for Women, Shaheed Benazirabad, Sindh, Pakistan
Summiya Ali Department of Obstetrics & Gynecology, People's University of Medical and Health Sciences for Women, Shaheed Benazirabad, Sindh, Pakistan
Zara Department of Obstetrics & Gynecology, People's University of Medical and Health Sciences for Women, Shaheed Benazirabad, Sindh, Pakistan
Seema Department of Obstetrics & Gynecology, People's University of Medical and Health Sciences for Women, Shaheed Benazirabad, Sindh, Pakistan

DOI:

https://doi.org/10.70749/ijbr.v3i4.2637

Keywords:

Acne, PCOS, Hirsutism, Skin manifestations, Acne

Abstract

Background: Hirsutism, androgenic alopecia, acne, and seborrhea are among the skin abnormalities associated with PCOS that are brought on by hyperandrogenemia. Many women with PCOS also have dark keratosis, which is linked to insulin resistance. Objective: The purpose of this study is to ascertain the frequency of cutaneous symptoms linked to PCOs. Materials and Methods: This cross-sectional study was conducted at the People's University of Medical and Health Sciences for Women, Shaheed Benazirabad, Sindh, from August to December of 2024. One hundred PCO patients between the ages of 15 and 45 years were recruited for the study. Androgenic alopecia was evaluated using Ludwig's classification. A modified Ferriman Gallway (F-G) score was used to determine the severity of hirsutism, Acanthosis nigricans is a long-term skin disorder that affects the neck, major flexures, and acral regions and is characterized by velvety thickening and hyperpigmentation. Patients under the age of 15, those with thyroid, pituitary, hypothalamic, or adrenal disorders, and those on any hormonal, lipid-lowering, or hypoglycemic treatments were not allowed to participate in the trial. Results: The study's age range was 18 to 45 years old, with a mean age of 28.81 ± 4.83 years. PCOS lasted an average of 3.68 ± 1.60 years. According to study, hirsutism, acne, female pattern hair loss, acanthosis nigricans, seborrhea, striae, and acrochordons were found in 75.63%, 65.0%, 34.38%, 30.0%, 24.38%, 11.88%, and 11.25% of PCOS patients, respectively. Conclusion: Dermatological signs are part of the phenotypic profile of PCOS. In addition to being crucial in the diagnosis of PCOS, they may have long-term psychological and aesthetic effects on the patient's social and quality of life.

Downloads

Download data is not yet available.

References

1. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016; 31(12):2841-55.

https://doi.org/10.1093/humrep/dew218

2. Sadeghi HM, Adeli I, Calina D, Docea AO, Mousavi T, Daniali M,et al. Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing. International Journal Medical Science. 2022 Jan 6; 23(2):583.

https://doi.org/10.3390/ijms23020583.

3. Tavares A, Rêgo Barros RC. The Prevalence of Metabolic Syndrome in the Different Phenotypes of Polycystic Ovarian. Syndrome. Rev Bras Ginecol Obstet. 2019 Jan;41(1):37-43.

https://doi.org/10.1055/s-0038-1676568.

4. Zivanovic D, Masirevic I, Ruzicka T, Braun-Falco M, Nikolic M. Pyoderma gangrenosum, acne, suppurative hidradenitis (PASH) and polycystic ovary syndrome: Coincidentally or aetiologically connected? Australas J Dermatol. 2017 May;58(2):e54-e59.

https://doi.org/10.1111/ajd.12438.

5. Livadas S, Anagnostis P, Bosdou JK, Bantouna D, Paparodis R. Polycystic ovary syndrome and type 2 diabetes mellitus: A state-of-the-art review. World J Diabetes. 2022 Jan 15; 13(1):5 26.

https://doi.org/10.4239/wjd.v13.i1.5.

6. Johnson JE, Daley D, Tarta C, Stanciu PI. Risk of endometrial cancer in patients with polycystic ovarian syndrome: A meta analysis. Oncol Lett. 2023 Mar 8;25(4):168.

https://doi.org/10.3892/ol.2023.13754.

7. Bakhtiyar K, Beiranvand R, Ardalan A, Almasian A, Badrizadeh A, Bastami F, et al. An investigation of the effects of infertility on Women’s quality of life: a case-control study. 2019 Sep; 19(1):114 -23.

https://doi.org/10.1186/s12905-019-0805-3.

8. Popa ML, Popa AC, Tanase C, Gheorghisan-Galateanu AA. Acanthosis nigricans: To be or not to be afraid. Oncol Lett. 2019 May; 17(5):4133-4138.

https://doi.org/10.3892/ol.2018.9736.

9. Moghadam ZB, Fereidooni B, Saffari M, Montazeri A. Measures of health-related quality of life in PCOS women: a systematic review. International journal of women's health. 2018 Aug 1:10:397-408.

https://doi.org/10.2147/IJWH.S165794.

10. Keen M, Shah I, Sheikh G. Cutaneous manifestations of polycystic ovary syndrome: A cross-sectional clinical study. Indian Dermatol Online J. 2017;8(2):104.

https://doi.org/10.4103/2229-5178.202275

11. Abusailik MA, Muhanna AM, Almuhisen AA, Alhasanat AM, Alshamaseen AM, Bani Mustafa SM, et al. Cutaneous manifestation of polycystic ovary syndrome. Dermatol Reports. 2021 Sep 15; 13(2):8799.

https://doi.org/10.4081/dr.2021.8799.

12. Ezeh U, Huang A, Landay M, Azziz R. Long-term response of hirsutism and other hyperandrogenic symptoms to combination therapy in polycystic ovary syndrome. Journal of Women's Health. 2018 Jul 10.1089/jwh.2017.6833 1; 27(7):892-902. DOI:

13. Spritzer PM, Barone CR, Oliveira FB. Hirsutism in Polycystic Ovary Syndrome: Pathophysiology and Management. Curr Pharm Des. 2016 Oct; 22(36):5603-5613.

https://doi.org/10.2174/1381612822666160720151243.

14. Spritzer PM, Marchesan LB, Santos BR, Fighera TM. Hirsutism, Normal Androgens and Diagnosis of PCOS. Diagnostics (Basel). 2022 Aug 9; 12(8):1922.

https://doi.org/10.3390/diagnostics12081922.

15. Chhabra S, Gautam RK, Kulshreshtha B, Prasad A, Sharma N. Hirsutism: A Clinico-investigative Study. Int Journal Trichology. 2012 Oct; 4(4):246-50.

https://doi.org/10.4103/09747753.111204.

16. Tehrani FR, Gandevani SB, Yarandi RB, Naz MSG, Carmina E. Prevalence of acne vulgaris among women with polycystic ovary syndrome: a systemic review and meta-analysis. Gynecol Endocrinol. 2021 May;

https://doi.org/10.1080/09513590.2020.1859474.

17. Chanyachailert P, Chularojanamontri L, Chantrapanichkul P, Tuchinda P, Wongwananuruk T, Sardod P, et al. Adult female acne: Clinical characteristics and factors significantly associated with polycystic ovary syndrome. Australas Journal Dermatology. 2021

https://doi.org/10.1111/ajd.13700.

18. Yerram C, Rao GV, Kilaru KR. Study of cutaneous manifestations in patients with polycystic ovarian syndrome attending a tertiary care centre. Int J Res. 2019 Jul;5:481.

https://doi.org/10.18203/issn.2455-4529.intjresdermatol20193229

19. Jain P, Jain SK, Singh A, Goel S. Pattern of dermatologic manifestations in polycystic ovarian disease cases from a tertiary care hospital. Int J Adv Med. 2018;5:197-201.

https://doi.org/10.18203/2349-3933.ijam20180084

20. Singh A, Chaudhary RKP. Study of Cutaneous Manifestations of Polycystic Ovarian Syndrome, JMSCR. 2017;5(4):21177-82.

https://doi.org/10.18535/jmscr/v5i4.228

21. Das A, Datta D, Kassir M, Wollina U, Galadari H, Lotti T, et al. Acanthosis nigricans: A review. Journal of Cosmet Dermatology. Aug;19(8):1857-1865.

https://doi.org/10.1111/jocd.13544

22. Keen MA, Shah IH, Sheikh G. Cutaneous Manifestations of Polycystic Ovary Syndrome: A Cross-Sectional Clinical Study. Indian Dermatol Online J. 2017 Mar-Apr; 8(2):104-110.

https://doi.org/10.4103/2229-5178.202275.

23. Charnvises K, Weerakiet S, Tingthanatikul Y, Wansumrith S, Chanprasertyothin S, Rojanasakul A. Acanthosis nigricans: clinical predictor of abnormal glucose tolerance in Asian women with polycystic ovary syndrome. Gynecol Endocrinol. 2005 Sep; 21(3):161-4.

https://doi.org/10.1080/09513590500216776.

24. Ozdemir S, Ozdemir M, Görkemli H, Kiyici A, Bodur S. Specific dermatologic features of the polycystic ovary syndrome and its association with biochemical markers of the metabolic syndrome and hyperandrogenism. Acta Obstet Gynecol Scand. 2010; 89(2):199-204.

https://doi.org/10.3109/00016340903353284

25. Keen MA, Shah IH, Sheikh G. Cutaneous Manifestations of Polycystic Ovary Syndrome: A Cross-Sectional Clinical Study. Indian Dermatol Online J. 2017 Mar-Apr; 8(2):104-110.

https://doi.org/10.4103/2229-5178.202275.

26. Quinn M, Shinkai K, Pasch L, Kuzmich L, Cedars M, Huddleston H. Prevalence of androgenic alopecia in patients with polycystic ovary syndrome and characterization of associated clinical and biochemical features. Fertil Steril. 2014 Apr; 101(4):1129-34.

https://doi.org/10.1016/j.fertnstert.2014.01.003.

27. Kaur S, Gupta SK, Juneja SK, Kaur S, Rani M. Study of cutaneous manifestations of polycystic ovarian syndrome. Int J Reprod Contracept Obstet Gynecol 2020;9:1627-31.

https://doi.org/10.18203/2320-1770.ijrcog20201235

28. Gowri BV, Chandravathi PL, Sindhu PS, Naidu KS. Correlation of skin changes with hormonal changes in polycystic ovarian syndrome: A cross-sectional study clinical study. Indian J Dermatol. 2015;60:419.

https://doi.org/10.4103/0019-5154.160505

29. Chang WY, Knochenhauer ES, Bartolucci AA, Azziz R. Phenotypic spectrum of polycystic ovary syndrome: Clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril. 2005;83:1717–23.

https://doi.org/10.1016/j.fertnstert.2005.01.096

30. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745–9.

https://doi.org/10.1210/jc.2003-032046

31. Saxena P, Prakash A, Nigam A, Mishra A. Polycystic ovarian syndrome: Is obesity a sine qua non? A clinical, hormonal and metabolic assessment in relation to body mass index. Indian J Endocr Metb. 2012;16:996–9.

https://doi.org/10.4103/2230-8210.103011